The PTAB has denied institution of inter partes review of two Abbvie patents that relate to HUMIRA (adalimumab). On February 9, 2018, the PTAB denied Sandoz’s IPR2017-01824 on U.S. Patent No. 9,512,216, which is directed to a method of treating plaque psoriasis by subcutaneously administering a claimed regimen of adalimumab. On the same day, the PTAB denied Sandoz’s IPR2017-10823 on U.S Patent No. 8,802,100 (the “’100 patent”), which is directed to stable aqueous pharmaceutical formulations comprising an anti-TNFα antibody. The PTAB previously denied institution of three IPRs directed formulation patents related to the ‘100 patent, filed by Amgen and Coherus.
Big Molecule Watch will continue to bring you updates on IPRs related to biologics and to post important documents on our IPR tracker page.
The post PTAB Denies Institution Of IPR On Two Humira Patents appeared first on Big Molecule Watch.